Article | Published:

Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis

Oncogenevolume 37pages14301444 (2018) | Download Citation

Abstract

Development of human tumors is driven by accumulation of alterations in tumor suppressor genes and oncogenes in cells. The POU1F1 transcription factor (also known Pit-1) is expressed in the mammary gland and its overexpression induces profound phenotypic changes in proteins involved in breast cancer progression. Patients with breast cancer and elevated expression of Pit-1 show a positive correlation with the occurrence of distant metastasis and poor overall survival. However, some mediators of Pit-1 actions are still unknown. Here, we show that CXCR4 chemokine receptor and its ligand CXCL12 play a critical role in the pro-tumoral process induced by Pit-1. We found that Pit-1 increases mRNA and protein in both CXCR4 and CXCL12. Knock-down of CXCR4 reduces tumor growth and spread of Pit-1 overexpressing cells in a zebrafish xenograft model. Furthermore, we described for the first time pro-angiogenic effects of Pit-1 through the CXCL12-CXCR4 axis, and that extravasation of Pit-1 overexpressing breast cancer cells is strongly reduced in CXCL12-deprived target tissues. Finally, in breast cancer patients, expression of Pit-1 in primary tumors was found to be positively correlated with CXCR4 and CXCL12, with specific metastasis in liver and lung, and with clinical outcome. Our results suggest that Pit-1-CXCL12-CXCR4 axis could be involved in chemotaxis guidance during the metastatic process, and may represent prognostic and/or therapeutic targets in breast tumors.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Anxo Martinez-Ordoñez and Samuel Seoane contributed equally to this work.

References

  1. 1.

    Lambert AW, Pattabiraman DR, Weinberg RA, Emerging biological principles of metastasis. Cell. 2017;68:670–91.

  2. 2.

    Valastyan S, Weinberg RA, Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–92.

  3. 3.

    Nguyen DXl, Bos PD, Massagué J, Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274–84.

  4. 4.

    Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.

  5. 5.

    Zlotnik A, Burkhardt AM, Homey B, Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11:597–606.

  6. 6.

    Lazennec G, Richmond A, Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010;16:133–44.

  7. 7.

    Burger JA, Kipps TJ, CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761–7.

  8. 8.

    Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64:8604–12.

  9. 9.

    Bachelder RE, Wendt MA, Mercurio AM, Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 2002;62:7203–06.

  10. 10.

    Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W, CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene. 2016;35:816–26.

  11. 11.

    Lefevre C, Imagawa M, Dana S, Grindlay J, Bodner M, Karin M, Tissue specific expression of the human growth hormone gene is conferred in part by the binding of a specific trans-acting factor. EMBO J. 1987;6:971–81.

  12. 12.

    Nelson C, Albert VR, Elsholtz HP, Lu LI-W, Rosenfeld MG, Activation of cell specific expression of rat growth hormone and prolactin genes by a common transcription factor. Science. 1988;239:1400–05.

  13. 13.

    Gil-Puig C, Blanco M, Garcia-Caballero T, Segura C, Perez-Fernandez R, Pit-1/GHF-1 and GH expression in MCF-7 human breast adenocarcinoma cell line. J Endocrinol. 2002;173:161–7.

  14. 14.

    Gil-Puig C, Seoane S, Blanco M, Macia M, Garcia-Caballero T, Segura C, et al. Pit-1 is expressed in normal and tumoral human breast and regulates growth hormone secretion and cell proliferation. Eur J Endocrinol. 2005;153:335–44.

  15. 15.

    Sendon-Lago J, Seoane S, Eiro N, Bermudez MA, Macia M, Garcia-Caballero T, et al. Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of metalloproteinase (MMP)-13. Breast Cancer Res. 2014;16:505.

  16. 16.

    Ben-Batalla I, Seoane S, Garcia-Caballero T, Gallego R, Macia M, Gonzalez LO, et al. Deregulation of the Pit-1 transcription factor in human breast cancer cells promotes tumor growth and metastasis. J Clin Invest. 2010;120:4289–302.

  17. 17.

    Gao Z, Xue K, Zhang L, Wei M, Over-expression of POU class 1 homeobox 1 transcription factor (Pit-1) predicts poor prognosis for breast cancer patients. Med Sci Monit. 2016;22:4121–25.

  18. 18.

    Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–31.

  19. 19.

    Lefort S, Thuleau A, Kieffer Y, Sirven P, Bieche I, Marangoni E, et al. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients. Oncogene. 2017;36:1211–22.

  20. 20.

    Chen HW, Du CW, Wei XL, Khoo US, Zhang GJ, Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer. Curr Mol Med. 2013;13:410–16.

  21. 21.

    DeVries ME, Kelvin AA, Xu L, Ran L, Robinson J, Kelvin DJ, Defining the origins and evolution of the chemokine/chemokine receptor system. J Immunol. 2006;176:401–15.

  22. 22.

    Doitsidou M, Reichman-Fried M, Stebler J, Koprunner M, Dorries J, Meyer D, et al. Guidance of primordial germ cell migration by the chemokine SDF-1. Cell. 2002;111:647–59.

  23. 23.

    Tiveron M-C, Cremer H, CXCL12/CXCR4 signaling in neuronal cell migration. Curr Opin Neurobiol. 2008;18:237–44.

  24. 24.

    Palevitch O, Abraham E, Borodovsky N, Levkowitz G, Zohar Y, Gothilf Y, Cxcl12a-Cxcr4b signaling is important for proper development of the forebrain GnRH system in zebrafish. Gen Comp Endocrinol. 2010;165:262–68.

  25. 25.

    Nica G, Herzog W, Sonntag C, Hammerschmidt M. Zebrafish pit1 mutants lack three pituitary cell types and develop severe dwarfism. Mol Endocrinol. 2004;18:1196–209.

  26. 26.

    Tulotta C, Stefanescu C, Beletkaia E, Bussmann J, Tarbashevich K, Schmidt T, et al. Inhibition of signaling between human CXCR4 and zebrafish ligands by the small molecule IT1t impairs the formation of triple-negative breast cancer early metastases in a zebrafish xenograft model. Dis Model Mech. 2016;9:141–53.

  27. 27.

    Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009;155:231–6.

  28. 28.

    Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer. 2011;129:225–32.

  29. 29.

    Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49:219–30.

  30. 30.

    Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun. 2007;359:716–22.

  31. 31.

    Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G, Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood. 2002;99:2703–11.

  32. 32.

    Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 2005;65:465–72.

  33. 33.

    Deshane J, Chen S, Caballero S, Grochot-Przeczek A, Was H, Li Calzi S, et al. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J Exp Med. 2007;20:605–18.

  34. 34.

    Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D, Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci Usa. 2013;110:E1291–300.

  35. 35.

    Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335–48.

  36. 36.

    Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006;244:113–20.

  37. 37.

    Peixoto P, Liu Y, Depauw S, Hildebrand M-P, Boykin DW, Bailly C, et al. Direct inhibition of the DNA-binding activity of POU transcription factors Pit-1 and Brn-3 by selective binding of a phenyl-furan-benzimidazole dication. Nucl Acids Res. 2008;36:3341–53.

  38. 38.

    Seoane S, Perez-Fernandez R, The vitamin D receptor represses transcription of the pituitary transcription factor Pit-1 gene without involvement of the retinoid X receptor. Mol Endocrinol. 2006;20:735–48.

  39. 39.

    Seoane S, Arias E, Sigueiro R, Sendon-Lago J, Martinez-Ordoñez A, Castelao E, et al. Pit-1 inhibits BRCA1 and sensitizes human breast tumors to cisplatin and vitamin D treatment. Oncotarget. 2015;16:14456–71.

  40. 40.

    Scala S, Molecular pathways: targeting the CXCR4-CXCL12 axis-untapped potential in the tumor microenvironment. Clin Cancer Res. 2015;21:4278–85.

  41. 41.

    Xu C, Zhao H, Chen H, Yao Q, CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther. 2015;9:4953–64.

  42. 42.

    Eiró N, Fernandez-Garcia B, Vázquez J, Del Casar JM, González LO, Vizoso FJ, A phenotype from tumor stroma based on the expression of metalloproteases and their inhibitors, associated with prognosis in breast cancer. Oncoimmunology. 2015;4:e992222. https://doi.org/10.4161/2162402X.2014.992222.

  43. 43.

    Zudaire E, Gambardella L, Kurcz C, Vermeren S, A computational tool for quantitative analysis of vascular networks. PLoS One. 2011;6:e27385. https://doi.org/10.1371/journal.pone.0027385.

Download references

Acknowledgements

This study was supported by Ministerio de Economía y Competividad (SAF2015-69221-R, MINECO/FEDER), and Conselleria de Cultura, Educación e Ordenacion Universitaria (GPC2014/001) to RP-F, and Ministerio de Educacion, FPU14/00548 to AM-O. We want to particularly acknowledge the patients and the BioBank Complejo Hospitalario Universitario de Santiago (CHUS) (PT17/0015/0002), integrated in the Spanish National Biobanks Network for its collaboration, to P. Peñas for providing biological samples, and to M. Fraile for help us with histological analyses.

Author information

Author notes

    Affiliations

    1. Department of Physiology-Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela, Spain

      • Anxo Martinez-Ordoñez
      • , Samuel Seoane
      • , Juan Sendon-Lago
      •  & Roman Perez-Fernandez
    2. Department of Genetics, University of Santiago de Compostela, Campus de Lugo, Lugo, Spain

      • Pablo Cabezas
      •  & Laura Sanchez
    3. Research Unit, Hospital Fundacion de Jove, Gijón, Spain

      • Noemi Eiro
      • , Luis O. Gonzalez
      •  & Francisco Vizoso
    4. Department of Obstetrics and Gynecology, University of Santiago de Compostela, Santiago de Compostela, Spain

      • Manuel Macia
    5. Department of Morphological Sciences, University of Santiago de Compostela, Santiago de Compostela, Spain

      • Tomas Garcia-Caballero

    Authors

    1. Search for Anxo Martinez-Ordoñez in:

    2. Search for Samuel Seoane in:

    3. Search for Pablo Cabezas in:

    4. Search for Noemi Eiro in:

    5. Search for Juan Sendon-Lago in:

    6. Search for Manuel Macia in:

    7. Search for Tomas Garcia-Caballero in:

    8. Search for Luis O. Gonzalez in:

    9. Search for Laura Sanchez in:

    10. Search for Francisco Vizoso in:

    11. Search for Roman Perez-Fernandez in:

    Conflict of interest

    The authors declare that they have no competing interests.

    Corresponding author

    Correspondence to Roman Perez-Fernandez.

    Electronic supplementary material

    About this article

    Publication history

    Received

    Revised

    Accepted

    Published

    Issue Date

    DOI

    https://doi.org/10.1038/s41388-017-0036-8

    Further reading